公司始(shi)建于2017年,位(wei)于全國第7大化工園區-東營(ying)港經濟開發區;集(ji)應(ying)用基礎研(yan)究、應(ying)用研(yan)究、工業化生(sheng)產(chan)、國際化銷售(shou)于-體(ti)(ti)的國家(jia)高新技術企業;主營(ying):小分子仿(fang)制(zhi)(zhi)原料藥(yao)與醫(yi)藥(yao)中(zhong)間體(ti)(ti)、創新藥(yao)定制(zhi)(zhi)加工(CDMO)、功能性精細化學品(pin)三大板塊; 2大生(sheng)產(chan)區總占地(di)578畝:仿(fang)制(zhi)(zhi)原料藥(yao)及中(zhong)間體(ti)(ti)生(sheng)產(chan)區、創新藥(yao)CDM0生(sheng)產(chan)區。
公司問題
1.希望以(yi)7.5%的投資回(hui)報率,收回(hui)資方股權(quan),但(dan)資方估(gu)值偏低,達不到預期
2、公(gong)司(si)總體戰(zhan)略(lve)模(mo)(mo)糊、經營戰(zhan)略(lve)模(mo)(mo)糊、職能戰(zhan)略(lve)模(mo)(mo)糊
3、組(zu)織結構亂,崗位責、權(quan)、利不清
4、留不住優秀年輕員工
方案落地成果
①成功以7.68%的投資(zi)回報率,收回資(zi)方(fang)股權
②設計公(gong)司戰略、經營戰略、職能(neng)戰略,明確未(wei)來(lai)的發展方向
③明確(que)崗位:貴(gui).權、利,并建(jian)立學習型組織(zhi)
④實施內部股(gu)權激(ji)勵(li),全員(yuan)持股(gu),留(liu)下優秀的年輕人才
⑤較2020年同比產值提升35%達到2.98億(yi),凈利潤到4500萬
⑥2025年(nian)創新(xin)藥獲批.上市后,計劃產值翻三(san)倍以(yi)上
公(gong)(gong)(gong)(gong)司地址:惠州公(gong)(gong)(gong)(gong)司 | 深(shen)圳公(gong)(gong)(gong)(gong)司 | 廣東公(gong)(gong)(gong)(gong)司 | 上海公(gong)(gong)(gong)(gong)司 | 江蘇公(gong)(gong)(gong)(gong)司 | 浙江公(gong)(gong)(gong)(gong)司 | 湖北公(gong)(gong)(gong)(gong)司 | 湖南公(gong)(gong)(gong)(gong)司 | 江(jiang)西公司 | 東莞松(song)山湖研發中心
Copyright ?2021 廣東(dong)遠(yuan)大方(fang)略(lve)管理咨詢有(you)限公司